Trial Profile
Phase 1-2 Study of an Immunotherapeutic Vaccine, DPX-Survivac With Low Dose Cyclophosphamide in Patients With Surgically Operable or Advanced Stage Ovarian, Fallopian Tube or Peritoneal Cancer
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 25 Sep 2021
Price :
$35
*
At a glance
- Drugs Maveropepimut-S (Primary) ; Cyclophosphamide
- Indications Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
- Focus Adverse reactions
- Sponsors Immunovaccine; IMV
- 03 May 2018 According to an IMV media release, Immunovaccine has changed its name to IMV.
- 20 Apr 2017 Status changed from active, no longer recruiting to completed.
- 25 Aug 2016 According to Immunovaccine media release, the company announced additional topline results from phase 1/1b trial of DPX-Survivac in ovarian cancer.